Overview

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Status:
Completed

Trial end date:
2021-06-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Docetaxel
Paclitaxel
Pevonedistat